Scarica l'app Stockscreener
0.4094
3.55%
0.0204
Scienture Holdings Inc Borsa (SCNX) Ultime notizie
Scienture Holdings stock jumps over 20% pre-market: Here's why - MSN
Scienture Holdings Company Profile & Introduction - Moomoo
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why - Sahm
Scienture Holdings (SCNX) Registration filing Summary - Quartr
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers - marketscreener.com
Scienture (SCNX) Prepares for Rezonopy Nasal Spray Launch - GuruFocus
Scienture completes manufacturing for naloxone spray launch By Investing.com - Investing.com Canada
Scienture completes manufacturing for naloxone spray launch - Investing.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers - marketscreener.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers - Moomoo
Scienture Holdings (SCNX) Slips 4% as Stock Tests Key Support Near $0.31Daily Profile - dars.gov.et
Scienture secures $11M debt financing for product launches - Investing.com
SCNX Q1 2026 Earnings: Significant EPS Beat Amid Pre-Revenue Stage as Scienture Outperforms Analyst ExpectationsEPS Surprise History - dars.gov.et
Price to sales forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to book forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to earnings forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX) - TradingView
SCNX Q1 2026 Earnings: EPS Surprise of 64.35% Amid Revenue Silence; Stock Declines 1.42%Profit Recovery Report - dars.gov.et
SCNX Forecast — Price Target — Prediction for 2027 - TradingView
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift Shares - dars.gov.et
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Scienture stock rises after adding 12.5M covered lives for Arbli - Investing.com Nigeria
Scienture stock rises after adding 12.5M covered lives for Arbli By Investing.com - Investing.com Australia
Scienture (SCNX) Advances Commercialization of Arbli - GuruFocus
Scienture expands payor coverage for Arbli by 12.5M lives - Investing.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - marketscreener.com
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Institutional Confidence - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64.35% Drives Stock RallyDividend Growth Analysis - dars.gov.et
SCNX Q1 2026 Earnings: Significant EPS Beat Signals Cost-Cutting ProgressRevenue Miss Report - DonanımHaber
SCNX Q1 2026 Earnings: Loss Narrower Than Expected as Stock Declines 4.66%Dividend Earnings Report - newsline.com
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings (SCNX) Q3 2025 earnings summary - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):